Vanda Pharmaceuticals Inc. (VNDA) stock
VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3056% below fair value
$3.67−0.08 (-2.13%)
Close on Nov 19, 2026Market cap $221.92MP/E –Yield –
Vanda Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Vanda Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$177.91M. For fiscal 2025 it was -$151.17M. The highest annual figure on record is $42.17M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$151.17M | – |
| FY2024 | Dec 31, 2024 | -$40.66M | – |
| FY2023 | Dec 31, 2023 | -$13.95M | -320.4% |
| FY2022 | Dec 31, 2022 | $6.33M | -85.0% |
| FY2021 | Dec 31, 2021 | $42.17M | +54.8% |
| FY2020 | Dec 31, 2020 | $27.24M | +19.4% |
| FY2019 | Dec 31, 2019 | $22.81M | +4.9% |
| FY2018 | Dec 31, 2018 | $21.74M | – |
| FY2017 | Dec 31, 2017 | -$16.90M | – |
| FY2016 | Dec 31, 2016 | -$18.57M | – |
| FY2015 | Dec 31, 2015 | -$40.19M | -300.3% |
| FY2014 | Dec 31, 2014 | $20.06M | – |
| FY2013 | Dec 31, 2013 | -$21.20M | – |
| FY2012 | Dec 31, 2012 | -$29.18M | – |
| FY2011 | Dec 31, 2011 | -$10.71M | -221.1% |
| FY2010 | Dec 31, 2010 | $8.84M | – |
| FY2009 | Dec 31, 2009 | -$35.95M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$23.52M | – |
| Q2 FY2026 | Jun 30, 2026 | -$63.81M | – |
| Q1 FY2026 | Mar 31, 2026 | -$50.22M | – |
| Q4 FY2025 | Dec 31, 2025 | -$40.35M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -$38.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$41.03M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.15M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.24M | -560.8% |
| Q4 FY2023 | Dec 31, 2023 | -$7.09M | -207.0% |
| Q3 FY2023 | Sep 30, 2023 | -$6.00M | -253.4% |
| Q2 FY2023 | Jun 30, 2023 | -$2.87M | -182.8% |
| Q1 FY2023 | Mar 31, 2023 | $2.00M | – |
| Q4 FY2022 | Dec 31, 2022 | $6.63M | -23.2% |
| Q3 FY2022 | Sep 30, 2022 | $3.91M | -63.9% |
| Q2 FY2022 | Jun 30, 2022 | $3.46M | -72.0% |
| Q1 FY2022 | Mar 31, 2022 | -$7.67M | -174.2% |
| Q4 FY2021 | Dec 31, 2021 | $8.64M | -17.4% |
| Q3 FY2021 | Sep 30, 2021 | $10.82M | +39.7% |
| Q2 FY2021 | Jun 30, 2021 | $12.37M | +34.9% |
| Q1 FY2021 | Mar 31, 2021 | $10.34M | – |
| Q4 FY2020 | Dec 31, 2020 | $10.45M | +146.3% |
| Q3 FY2020 | Sep 30, 2020 | $7.74M | -28.0% |
| Q2 FY2020 | Jun 30, 2020 | $9.17M | -7.3% |
| Q1 FY2020 | Mar 31, 2020 | -$125.00K | – |
| Q4 FY2019 | Dec 31, 2019 | $4.24M | -53.6% |
| Q3 FY2019 | Sep 30, 2019 | $10.76M | +72.6% |
| Q2 FY2019 | Jun 30, 2019 | $9.90M | +152.9% |
| Q1 FY2019 | Mar 31, 2019 | -$2.09M | -185.5% |
| Q4 FY2018 | Dec 31, 2018 | $9.15M | – |
| Q3 FY2018 | Sep 30, 2018 | $6.23M | – |
| Q2 FY2018 | Jun 30, 2018 | $3.91M | – |
| Q1 FY2018 | Mar 31, 2018 | $2.44M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.15M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.92M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.92M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.91M | – |
| Q4 FY2016 | Dec 31, 2016 | -$654.00K | – |
See a number that looks wrong?